TY - JOUR
T1 - Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis
AU - Fiorentino, David F.
AU - Kuo, Karen
AU - Chung, Lorinda
AU - Zaba, Lisa
AU - Li, Shufeng
AU - Casciola-Rosen, Livia
N1 - Funding Information:
Drs Fiorentino and Rosen are supported by National Institutes of Health (NIH) AR062615-01A1 . Dr Rosen is supported by NIH RO1 AR-44684 and the Donald and Dorothy Stabler Foundation . The Johns Hopkins Rheumatic Diseases Research Core Center, where the assays were performed, is supported by NIH P30-AR-053503 .
Publisher Copyright:
© 2014 American Academy of Dermatology, Inc.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Background Antibodies against transcriptional intermediary factor (TIF)-1γ are associated with malignancy in dermatomyositis (DM). Identification of clinical findings associated with anti-TIF-1γ antibodies in DM is a high priority for both patient diagnosis and risk assessment. Objective We sought to define the clinical phenotype of patients with anti-TIF-1γ DM. Methods Using a novel, sensitive, and specific assay for anti-TIF-1γ antibodies, we retrospectively tested plasma from 134 adult patients with DM and examined associations between anti-TIF-1γ antibodies and particular clinical and laboratory features. Results In all, 55 (41%) patients had autoantibodies to TIF-1γ. Anti-TIF-1γ positive patients were less likely to have systemic features including interstitial lung disease, Raynaud phenomenon, and arthritis/arthralgia. Patients with TIF-1γ autoantibodies had more extensive skin involvement, and some patients manifested characteristic findings including palmar hyperkeratotic papules, psoriasis-like lesions and a novel finding of hypopigmented and telangiectatic ("red on white") patches. Limitations This was a retrospective study from a single tertiary referral center. Conclusion TIF-1γ is the most commonly targeted DM-specific autoantigen in adults in a large US cohort. Although these patients tend to have less systemic involvement, their skin disease is often extensive and characteristic. Recognition of cutaneous findings in anti-TIF-1γ positive patients may allow more accurate and timely diagnosis and effective treatment of patients with DM.
AB - Background Antibodies against transcriptional intermediary factor (TIF)-1γ are associated with malignancy in dermatomyositis (DM). Identification of clinical findings associated with anti-TIF-1γ antibodies in DM is a high priority for both patient diagnosis and risk assessment. Objective We sought to define the clinical phenotype of patients with anti-TIF-1γ DM. Methods Using a novel, sensitive, and specific assay for anti-TIF-1γ antibodies, we retrospectively tested plasma from 134 adult patients with DM and examined associations between anti-TIF-1γ antibodies and particular clinical and laboratory features. Results In all, 55 (41%) patients had autoantibodies to TIF-1γ. Anti-TIF-1γ positive patients were less likely to have systemic features including interstitial lung disease, Raynaud phenomenon, and arthritis/arthralgia. Patients with TIF-1γ autoantibodies had more extensive skin involvement, and some patients manifested characteristic findings including palmar hyperkeratotic papules, psoriasis-like lesions and a novel finding of hypopigmented and telangiectatic ("red on white") patches. Limitations This was a retrospective study from a single tertiary referral center. Conclusion TIF-1γ is the most commonly targeted DM-specific autoantigen in adults in a large US cohort. Although these patients tend to have less systemic involvement, their skin disease is often extensive and characteristic. Recognition of cutaneous findings in anti-TIF-1γ positive patients may allow more accurate and timely diagnosis and effective treatment of patients with DM.
KW - Cutaneous Dermatomyositis Assessment and Severity Index
KW - autoantibodies
KW - dermatomyositis
KW - malignancy
KW - phenotype
KW - transcriptional intermediary factor-1γ
UR - http://www.scopus.com/inward/record.url?scp=84925445234&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925445234&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2014.12.009
DO - 10.1016/j.jaad.2014.12.009
M3 - Article
C2 - 25595720
AN - SCOPUS:84925445234
SN - 0190-9622
VL - 72
SP - 449
EP - 455
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 3
ER -